The American College of Obstetricians and Gynecologists recommends that patients stop taking GLP-1 weight-loss drugs one to two months before a pregnancy due to unclear safety data, while new animal research shows semaglutide quickly reduces uterine blood flow and fetal oxygen levels.
Data from the American College of Obstetricians and Gynecologists indicates that roughly 1 in every 300 women encounter GLP-1 medications during pregnancy. The organization released guidance in late October recommending that patients discontinue use one to two months before conception, as lawsuits and studies raise questions about potential side effects.
Existing research does not suggest a high risk of congenital issues from taking the drugs before or during pregnancy, but available safety data remains limited. Nearly 25 million U.S. women aged 18 to 44 are eligible for GLP-1 medications, and over 40% of pregnancies in the country are unplanned, according to Medscape data.
What sheep studies reveal about fetal oxygen
A recent animal study published in the journal Heart, Lung and Circulation found that a single dose of semaglutide reduced blood flow to the uterus and lowered oxygen levels in the developing fetus within two hours. These cardiovascular shifts were monitored by investigators hailing from Adelaide University, the University of Toronto, and the Hospital for Sick Children in Toronto through MRI scans performed on a group of seven pregnant sheep.
“While weight-loss medications have become incredibly popular, there's still a lot we don't know about how they might affect a developing baby,” Lock said. Senior researcher Janna Morrison said that while the findings highlight potential risks to fetal development, the work examined only short-term exposure.
“Our findings suggest a potential risk to fetal development, but we haven’t yet established whether these short-term changes affect fetal growth, what happens over a longer period of semaglutide use or whether similar effects could occur in human pregnancies,” Morrison said, as reported by Medical Xpress.
For mothers using GLP-1 medications while breastfeeding, the ACOG recommends carefully monitoring infant neonatal weight gain. The group advises against taking the medications while breastfeeding preterm infants.
Current studies do not indicate that GLP-1 drugs pass into human milk, but both obesity and malnutrition can alter breast milk composition. Parents should discuss a care plan with their physicians postpartum.
“This is a fast-moving area of research, so for now we need to proceed with caution and reassess as more data becomes available,” Yvette LaCoursiere, who serves as an author of the guidelines and holds a position as a professor of obstetrics, gynecology and reproductive sciences at University of California at San Diego, stated within a press release highlighted by The Washington Post.
Frequently asked questions about GLP-1s and reproductive health
What are the risks for patients managing diabetes?
Patients using GLP-1s to control existing diabetes face rising glucose levels when stopping the medication, requiring tight follow-up care with maternal-fetal medicine specialists or endocrinologists.
